ABIOMED (NASDAQ:ABMD) Upgraded to Hold by BidaskClub

BidaskClub upgraded shares of ABIOMED (NASDAQ:ABMD) from a sell rating to a hold rating in a research note published on Thursday, BidAskClub reports.

Several other analysts have also recently weighed in on the stock. BTIG Research cut shares of ABIOMED from a buy rating to a neutral rating in a report on Thursday, August 1st. TheStreet cut shares of ABIOMED from a b- rating to a c+ rating in a report on Thursday, August 22nd. Guggenheim cut shares of ABIOMED from a buy rating to a neutral rating in a report on Friday, August 2nd. ValuEngine raised shares of ABIOMED from a sell rating to a hold rating in a report on Wednesday, September 4th. Finally, Leerink Swann raised their target price on shares of ABIOMED from $195.00 to $240.00 and gave the company an outperform rating in a report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and three have given a buy rating to the company’s stock. ABIOMED currently has an average rating of Hold and an average target price of $301.20.

Shares of ABMD traded up $0.49 during mid-day trading on Thursday, reaching $219.62. The stock had a trading volume of 385,600 shares, compared to its average volume of 641,749. The business’s fifty day moving average is $183.43 and its 200 day moving average is $225.93. The firm has a market cap of $9.82 billion, a price-to-earnings ratio of 61.01, a P/E/G ratio of 1.90 and a beta of 0.37. ABIOMED has a 52-week low of $155.02 and a 52-week high of $413.32.

ABIOMED (NASDAQ:ABMD) last issued its earnings results on Thursday, October 31st. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.93 by $0.10. The firm had revenue of $204.97 million for the quarter, compared to analysts’ expectations of $206.45 million. ABIOMED had a net margin of 26.92% and a return on equity of 19.89%. The firm’s revenue was up 12.8% compared to the same quarter last year. During the same quarter last year, the company earned $1.09 earnings per share. As a group, research analysts forecast that ABIOMED will post 4.32 EPS for the current fiscal year.

A number of institutional investors have recently made changes to their positions in ABMD. Executive Wealth Management LLC increased its stake in ABIOMED by 100.0% in the second quarter. Executive Wealth Management LLC now owns 100 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 50 shares during the last quarter. Kistler Tiffany Companies LLC purchased a new position in ABIOMED in the third quarter valued at approximately $34,000. Tompkins Financial Corp purchased a new position in ABIOMED in the second quarter valued at approximately $39,000. FTB Advisors Inc. purchased a new position in ABIOMED in the second quarter valued at approximately $48,000. Finally, Captrust Financial Advisors increased its stake in ABIOMED by 484.8% in the second quarter. Captrust Financial Advisors now owns 193 shares of the medical equipment provider’s stock valued at $50,000 after purchasing an additional 160 shares during the last quarter. Institutional investors own 91.19% of the company’s stock.

About ABIOMED

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

See Also: Quiet Period Expirations Explained

Analyst Recommendations for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.